Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | May 05, 2020 | May 08, 2020 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | February 23, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 05, 2020 · Filed May 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,973.6942 |
Reported balance
After 2020-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 968.6942 · Balance 17,973.6942 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2: These shares include 1,849 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan, and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
F2: These shares include 1,849 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan, and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
IDEXX LABORATORIES INC /DE
Report date February 23, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,696 |
Ending reported balance
After 2021-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-23 · Exercise / conversion · Acquired 3,046 · Balance 17,742 Row 2 · 2021-02-23 · Sale · Disposed 3,046 · Balance 14,696 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.28 · Expires 2027-05-02 | Direct | 0 |
Reported balance
After 2021-02-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-23 · Exercise / conversion · Disposed 3,046 · Balance 0 F2: Not applicable. F1: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 3, 2018.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2014 Filed Feb 14, 2014 21:34 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $63.11 | $0.00 |
DisclosureSEC source: 0001127602-14-006489 · form4.xml · derivative · entry 4 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 17,000 shares Expires 2019-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 21:34 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 20,000 | $123.53 | $2,470,680.00 |
DisclosureSEC source: 0001127602-14-006489 · form4.xml · nonDerivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,549 F1 · price: The price reported is an average price. The prices ranged from $123.26 to $123.78 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include 165 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 21:34 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 3,000 | $58.43 | $175,290.00 |
DisclosureSEC source: 0001127602-14-006489 · form4.xml · nonDerivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2014 Filed Feb 14, 2014 21:34 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 17,000 | $63.11 | $1,072,870.00 |
DisclosureSEC source: 0001127602-14-006489 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $54.69 | $0.00 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · derivative · entry 6 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · derivative · entry 5 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 2,000 shares Expires 2020-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,421 | $105.84 | $150,404.47 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 4 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,477 F2 · price: The price reported is an average price. The prices ranged from $105.8301 to $105.85 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F3 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 7,000 | $105.70 | $739,895.80 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 3 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,898 F1 · price: The price reported is an average price. The prices ranged from $105.67 to $105.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $54.69 | $273,450.00 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2013 Filed May 20, 2013 23:15 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 2,000 | $58.43 | $116,860.00 |
DisclosureSEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:55 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014799 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,898 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2012 Filed May 1, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $71.64 Strike: $71.64 | $358,200.00 |
DisclosureSEC source: 0001127602-12-015223 · form4.xml · derivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-04-27 Read SEC document |
| April 27, 2012 Filed May 1, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-015223 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 F1 · shares: The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the "Director Program") and will vest one year from the grant date because the director has less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 26 Dividend Equivalents ("DEs") granted pursuant to the Director Program. The acquisition of DEs had previously been reported in Table II of the director's Form 4 filings prior to the Company implementing a qualifying dividend reinvestment plan in 2012. DEs are credited on the director's unvested, and vested but deferred, RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| December 08, 2011 Filed Dec 13, 2011 00:06 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 8.2442 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-031951 · form4.xml · derivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16.9059 Underlying: Common Stock · 8.2442 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 08, 2011 Filed Sep 12, 2011 21:11 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 8.6617 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-025056 · form4.xml · derivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8.6617 Underlying: Common Stock · 8.6617 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:12 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $54.69 Strike: $54.69 | $273,450.00 |
DisclosureSEC source: 0001127602-11-013856 · form4.xml · derivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-04-25 Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:12 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013856 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,539 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 23:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $58.43 Strike: $58.43 | $292,150.00 |
DisclosureSEC source: 0001127602-10-012370 · form4.xml · derivative · entry 2 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-26 Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 23:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-012370 · form4.xml · nonDerivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,711 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| July 30, 2009 Filed Jul 31, 2009 16:07 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 20,000 | $63.11 Strike: $63.11 | $1,262,200.00 |
DisclosureSEC source: 0001127602-09-016427 · form4.xml · derivative · entry 1 HENDERSON REBECCA M · CIK 0001254748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2019-07-30 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.